INTERCEPT PHARMACEUTICALS IN - NOTE 2.000% 5/1

CUSIP: 45845PAB4

Q4 2020 13F Holders as of 31 Dec 2020

Type / Class
Debt / NOTE 2.000% 5/1
Market price (% of par)
60.04%
Total 13F principal
$224,162,000
Principal change
-$278,000
Total reported market value
$135,668,461
Number of holders
19
Value change
-$2,969,434
Number of buys
8
Number of sells
10

Quarterly Holders Quick Answers

What is CUSIP 45845PAB4?
CUSIP 45845PAB4 identifies 45845PAB4 - INTERCEPT PHARMACEUTICALS IN - NOTE 2.000% 5/1 in SEC institutional holdings data.

Need full ownership history?
Open the full security ownership history page.

Institutional Holders of INTERCEPT PHARMACEUTICALS IN - NOTE 2.000% 5/1 as of Q4 2020

As of 31 Dec 2020, INTERCEPT PHARMACEUTICALS IN - NOTE 2.000% 5/1 was held by 19 institutional bondholders reporting positions in Form 13F filings. These institutions reported holding $224,162,000 in principal (par value) of the bond. The largest 10 bondholders included HIGHBRIDGE CAPITAL MANAGEMENT LLC, FRANKLIN RESOURCES INC, SOROS FUND MANAGEMENT LLC, LAZARD ASSET MANAGEMENT LLC, FMR LLC, BNP PARIBAS ARBITRAGE, SA, Context Capital Management, LLC, MORGAN STANLEY, Shaolin Capital Management LLC, and Opti Capital Management, LP. This page lists 19 institutional bondholders reporting positions for the Q4 2020 filing period.
Investor Option Weight % Change % Value $ * Price (% of par) Principal Share Change Activity Report Period
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.